SENISCA secures 3.7 million euros to fight aging with RNA-based therapies
Longevity Technology - 18-Mar-2024Developing senotherapeutics to target cellular senescence and treat age-related diseases
Join the club for FREE to access the whole archive and other member benefits.
Co-founder and CEO of QantX, Non-Executive Director at SENISCA
Richard is the co-founder and CEO of QantX. He has been involved in technology businesses for 40 years, leading at the forefront of major paradigm shifts in the industry. He is an innovation driven entrepreneur and has wide experience of building and scaling businesses through new technology, venturing, and creating disruptive business models. His most recent role before QantX, was as a Senior Director of Oracle Corporation where he was part of the Global Enterprise Cloud team. Richard has joined SENISCA as the appointed Investor Director for QantX.
Visit website: https://www.crunchbase.com/person/richard-haycock-6928
See also: SENISCA - University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing
Details last updated 13-Jan-2024
University of Exeter spinout developing senotherapeutic interventions through modulation of dysregulated RNA splicing
Developing senotherapeutics to target cellular senescence and treat age-related diseases